SLC5A2 and congestive heart failure: SGLT2 inhibitors promotes blood glucose excretion by inhibiting reabsorption of glucose from glomerular filtrate and also increases uric acid excretion, which are cardioprotective and associated with cardiovascular complications and congestive heart failure [52, 53].